JP2005512574A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005512574A5 JP2005512574A5 JP2003554914A JP2003554914A JP2005512574A5 JP 2005512574 A5 JP2005512574 A5 JP 2005512574A5 JP 2003554914 A JP2003554914 A JP 2003554914A JP 2003554914 A JP2003554914 A JP 2003554914A JP 2005512574 A5 JP2005512574 A5 JP 2005512574A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- acid sequence
- amino acid
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001184 polypeptide Polymers 0.000 claims 45
- 108090000765 processed proteins & peptides Proteins 0.000 claims 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims 45
- 108010087819 Fc receptors Proteins 0.000 claims 19
- 102000009109 Fc receptors Human genes 0.000 claims 19
- 150000001413 amino acids Chemical group 0.000 claims 19
- 238000000034 method Methods 0.000 claims 19
- 150000007523 nucleic acids Chemical class 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 230000004071 biological effect Effects 0.000 claims 7
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- -1 6-His tag Proteins 0.000 claims 2
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims 2
- 101000913079 Homo sapiens IgG receptor FcRn large subunit p51 Proteins 0.000 claims 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 2
- 241000282567 Macaca fascicularis Species 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 102000005720 Glutathione transferase Human genes 0.000 claims 1
- 108010070675 Glutathione transferase Proteins 0.000 claims 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010079246 OMPA outer membrane proteins Proteins 0.000 claims 1
- 241000282577 Pan troglodytes Species 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 102000002933 Thioredoxin Human genes 0.000 claims 1
- VJBCNMFKFZIXHC-UHFFFAOYSA-N azanium;2-(4-methyl-5-oxo-4-propan-2-yl-1h-imidazol-2-yl)quinoline-3-carboxylate Chemical compound N.N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O VJBCNMFKFZIXHC-UHFFFAOYSA-N 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 210000004989 spleen cell Anatomy 0.000 claims 1
- 108060008226 thioredoxin Proteins 0.000 claims 1
- 229940094937 thioredoxin Drugs 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/027,736 US6911321B2 (en) | 2001-12-19 | 2001-12-19 | Non-human primate Fc receptors and methods of use |
| PCT/US2002/038805 WO2003054213A2 (en) | 2001-12-19 | 2002-12-03 | NON-HUMAN PRIMATE Fc RECEPTORS AND METHODS OF USE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005512574A JP2005512574A (ja) | 2005-05-12 |
| JP2005512574A5 true JP2005512574A5 (enExample) | 2006-07-13 |
Family
ID=21839483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003554914A Withdrawn JP2005512574A (ja) | 2001-12-19 | 2002-12-03 | 非ヒト霊長類Fcレセプターおよびその利用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US6911321B2 (enExample) |
| EP (1) | EP1456222A4 (enExample) |
| JP (1) | JP2005512574A (enExample) |
| AU (1) | AU2002357071A1 (enExample) |
| CA (1) | CA2466885A1 (enExample) |
| IL (1) | IL161543A0 (enExample) |
| WO (1) | WO2003054213A2 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US20070148171A1 (en) * | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
| US20080254027A1 (en) * | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| JP3993783B2 (ja) * | 2002-04-04 | 2007-10-17 | 株式会社小糸製作所 | 車両用灯具の設計方法、設計システム、プログラム、及び記録媒体 |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| BRPI0406724A (pt) * | 2003-01-13 | 2005-12-20 | Macrogenics Inc | Proteìna de fusão dimérica, métodos de tratar, prevenir ou melhorar um ou mais sintomas de um distúrbio autoimune e um ou mais sintomas de púrpura trombocitopênica idiopática, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, método de produzir recombinantemente o polipeptìdeo, polipeptìdeo isolado, fragmento de qualquer um dos polipeptìdeos, e, molécula de ácido nucleico isolada |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US20070275460A1 (en) * | 2003-03-03 | 2007-11-29 | Xencor.Inc. | Fc Variants With Optimized Fc Receptor Binding Properties |
| US8388955B2 (en) * | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20070148170A1 (en) * | 2005-10-03 | 2007-06-28 | Desjarlais John R | Fc Variants With Optimized Fc Receptor Binding Properties |
| US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| CA2545603A1 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| ES2371468T3 (es) * | 2003-11-26 | 2012-01-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | SUSTANCIA QUE SE UNE AL RECEPTOR HUMANO llb MEDIANTE Fc DE IgG (Fc? Rllb). |
| WO2005077981A2 (en) * | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| EP2053062A1 (en) * | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
| US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
| US20060074225A1 (en) * | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US20070135620A1 (en) * | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| BRPI0517837A (pt) | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
| WO2006076594A2 (en) * | 2005-01-12 | 2006-07-20 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| CA2625998C (en) | 2005-10-06 | 2015-12-01 | Xencor, Inc. | Optimized anti-cd30 antibodies |
| ME01786B (me) | 2006-08-14 | 2014-09-20 | Xencor Inc | Optimizovana antitela usmerena na cd19 |
| WO2008028068A2 (en) * | 2006-08-30 | 2008-03-06 | Genentech, Inc. | NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES |
| CA2660795C (en) | 2006-09-18 | 2014-11-18 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| US7580304B2 (en) * | 2007-06-15 | 2009-08-25 | United Memories, Inc. | Multiple bus charge sharing |
| ES2742268T3 (es) | 2007-12-26 | 2020-02-13 | Xencor Inc | Variantes de Fc con unión alterada a FcRn |
| US12492253B1 (en) | 2008-02-25 | 2025-12-09 | Xencor, Inc. | Anti-human C5 antibodies |
| WO2010068722A1 (en) | 2008-12-12 | 2010-06-17 | Medimmune, Llc | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| WO2011091078A2 (en) | 2010-01-19 | 2011-07-28 | Xencor, Inc. | Antibody fc variants with enhanced complement activity |
| JP5812627B2 (ja) * | 2010-03-10 | 2015-11-17 | 公益財団法人相模中央化学研究所 | 改良Fc受容体およびその製造方法 |
| US10611817B2 (en) | 2013-09-18 | 2020-04-07 | Tosoh Corporation | Fc-binding protein, method for producing said protein, and antibody adsorbent using said protein, and methods for purifying and identifying antibody using said adsorbent |
| SMT202000332T1 (it) * | 2014-04-08 | 2020-07-08 | Regeneron Pharma | Animali non umani aventi recettori fc-gamma umanizzati |
| CA3014466A1 (en) * | 2016-03-03 | 2017-09-08 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| AU2017379900B2 (en) | 2016-12-22 | 2024-12-05 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN111263813B (zh) | 2017-10-27 | 2023-10-17 | 东曹株式会社 | 耐碱性提高的Fc结合性蛋白质及其制造方法、使用该蛋白质的抗体吸附剂和分离抗体的方法 |
| EP4149534A4 (en) | 2020-05-12 | 2024-09-04 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF |
| WO2024232948A1 (en) * | 2023-05-05 | 2024-11-14 | Board Of Regents, The University Of Texas System | Multi-receptor natural killer cells |
| CN116769014A (zh) * | 2023-06-07 | 2023-09-19 | 河南省农业科学院动物免疫学重点实验室 | 一种牛IgG Fc受体boFcγRI的线性配体结合表位 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5189014A (en) * | 1979-12-03 | 1993-02-23 | Cowan Jr Fred M | Method of treating cellular Fc receptor mediated hypersensitivity immune disorders |
| US4737462A (en) * | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US5985599A (en) * | 1986-05-29 | 1999-11-16 | The Austin Research Institute | FC receptor for immunoglobulin |
| US5877396A (en) * | 1993-04-23 | 1999-03-02 | Sloan Kettering Institute For Cancer Research | Mice mutant for functional Fc receptors and method of treating autoimmune diseases |
| WO1994025570A1 (en) * | 1993-04-23 | 1994-11-10 | Sloan-Kettering Institute For Cancer Research | Method for screening for targets for anti-inflammatory or anti-allergic agents |
| US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6676927B1 (en) * | 1999-01-20 | 2004-01-13 | The Rockefeller University | Animal model and methods for its use in the selection of cytotoxic antibodies |
-
2001
- 2001-12-19 US US10/027,736 patent/US6911321B2/en not_active Expired - Fee Related
-
2002
- 2002-12-03 JP JP2003554914A patent/JP2005512574A/ja not_active Withdrawn
- 2002-12-03 EP EP02805540A patent/EP1456222A4/en not_active Withdrawn
- 2002-12-03 WO PCT/US2002/038805 patent/WO2003054213A2/en not_active Ceased
- 2002-12-03 AU AU2002357071A patent/AU2002357071A1/en not_active Abandoned
- 2002-12-03 CA CA002466885A patent/CA2466885A1/en not_active Abandoned
- 2002-12-03 IL IL16154302A patent/IL161543A0/xx unknown
-
2004
- 2004-07-13 US US10/896,840 patent/US20050054046A1/en not_active Abandoned
-
2006
- 2006-09-27 US US11/535,824 patent/US20070106069A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005512574A5 (enExample) | ||
| ES2322945T3 (es) | Metodos para la purificacion de proteina. | |
| EP1730198B1 (en) | Adzymes and uses thereof | |
| JP5522723B2 (ja) | 新規ポリペプチド,アフィニティークロマトグラフィー用材,及びイムノグロブリンの分離及び/又は精製方法 | |
| TWI598361B (zh) | Cx3cr1-結合多肽 | |
| Harari et al. | Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis | |
| AU2018390418A1 (en) | Engineered IL-2 FC fusion proteins | |
| KR20100084996A (ko) | 면역글로불린 단편을 이용한 생리활성 단백질 또는 펩타이드의 생산 방법 | |
| JP2016505251A5 (enExample) | ||
| CA2905141A1 (en) | Interleukin-2 muteins for the expansion of t-regulatory cells | |
| US20250195673A1 (en) | Compositions and methods for selective depletion of target molecules | |
| KR20170065026A (ko) | 대사 장애 치료용으로 이용되는 조성물 및 방법 | |
| WO2020099871A1 (en) | Single domain antibodies that bind human serum albumin | |
| CN113227134A (zh) | 抗体的Fc区变体 | |
| CN105518023A (zh) | Fab区域结合性肽 | |
| KR20220131221A (ko) | 바코드화된 xten 폴리펩티드 및 이의 조성물, 및 이의 제조 방법 및 사용 방법 | |
| CN113840835A (zh) | 结合分子 | |
| KR20110021723A (ko) | 단백질 정제 방법 및 단백질 정제용 친화성 컬럼 | |
| CN120051292A (zh) | Il-18融合蛋白以及生产il-18的方法 | |
| CA3206901A1 (en) | Paraoxonase fusion polypeptides and related compositions and methods | |
| WO2023235522A1 (en) | Compositions and methods for selective depletion of egfr target molecules | |
| JP2021525807A (ja) | ポリユビキチンリンカーに結合された線形多機能性マルチマー生体分子及びその用途 | |
| WO1995006737A1 (en) | Glycophorin binding protein (gbp130) fusion compositions | |
| CN100427506C (zh) | 从融合多肽制备感兴趣的多肽的方法 | |
| CN102977205A (zh) | 骨保护素变异蛋白 |